194 related articles for article (PubMed ID: 7828136)
1. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
[TBL] [Abstract][Full Text] [Related]
2. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.
Albers P; Bierhoff E; Neu D; Fimmers R; Wernert N; Müller SC
Cancer; 1997 May; 79(9):1710-6. PubMed ID: 9128986
[TBL] [Abstract][Full Text] [Related]
3. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Orazi A; Ulbright TM; Miller GA; Haidar JH; Donohue JP; Foster RS
Mod Pathol; 1995 Jun; 8(5):492-7. PubMed ID: 7545814
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.
Heidenreich A; Schenkmann NS; Sesterhenn IA; Mostofi FK; McCarthy WF; Heidenreich B; Moul JW
J Urol; 1997 Aug; 158(2):620-5. PubMed ID: 9224380
[TBL] [Abstract][Full Text] [Related]
6. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Ulbright TM; Albers J; Miller GA; Orazi A; Crabtree WN; Baniel J; Reister T; Sidner RA; Foster RS; Donohue JP
J Urol; 1996 Feb; 155(2):579-86. PubMed ID: 8558664
[TBL] [Abstract][Full Text] [Related]
7. [New parameters for prediction of pathological stage in clinical stage I non-seminomatous testicular tumors].
Albers P; Ulbright TM; Albers J; Miller GA; Foster RS; Donohue JP
Urologe A; 1995 Jul; 34(4):316-23. PubMed ID: 7676541
[TBL] [Abstract][Full Text] [Related]
8. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment.
Leibovitch I; Foster RS; Kopecky KK; Albers P; Ulbright TM; Donohue JP
J Clin Oncol; 1998 Jan; 16(1):261-8. PubMed ID: 9440751
[TBL] [Abstract][Full Text] [Related]
9. alpha-Catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage I nonseminomatous testicular cancer.
Spermon JR; De Wilde PC; Hanselaar AG; Schaafsma HE; Ruijter TE; Witjes JA; Van Moorselaar RJ
BJU Int; 2002 Feb; 89(3):278-84. PubMed ID: 11856111
[TBL] [Abstract][Full Text] [Related]
10. Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors.
de Riese WT; Albers P; Walker EB; Ulbright TM; Crabtree WN; Reister T; Foster RS; Donohue JP
Cancer; 1994 Aug; 74(4):1335-41. PubMed ID: 8055457
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.
Lewis DJ; Sesterhenn IA; McCarthy WF; Moul JW
J Urol; 1994 Aug; 152(2 Pt 1):418-23. PubMed ID: 8015085
[TBL] [Abstract][Full Text] [Related]
12. Quantitative DNA measurement by flow cytometry and image analysis of human nonseminomatous germ cell testicular tumors.
de Riese W; Walker EB; de Riese C; Ulbright TM; Crabtree WN; Messemer J; Jones JA; Hinkel A; Foster RS; Donohue JP
Urol Res; 1994; 22(4):213-20. PubMed ID: 7871632
[TBL] [Abstract][Full Text] [Related]
13. Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors.
De Riese WT; De Riese C; Ulbright TM; Walker EB; Messemer J; Jones JA; Reister T; Albers P; Allhoff EP; Foster RS
Int J Cancer; 1994 Jun; 57(5):628-33. PubMed ID: 8194868
[TBL] [Abstract][Full Text] [Related]
14. Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
Fernandez EB; Sesterhenn IA; McCarthy WF; Mostofi FK; Moul JW
J Urol; 1994 Oct; 152(4):1133-8. PubMed ID: 7915335
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.
Albers P; Siener R; Kliesch S; Weissbach L; Krege S; Sparwasser C; Schulze H; Heidenreich A; de Riese W; Loy V; Bierhoff E; Wittekind C; Fimmers R; Hartmann M;
J Clin Oncol; 2003 Apr; 21(8):1505-12. PubMed ID: 12697874
[TBL] [Abstract][Full Text] [Related]
16. [Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW; Engelmann UH
Urologe A; 1999 Mar; 38(2):168-78. PubMed ID: 10231939
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.
Cattoretti G; Becker MH; Key G; Duchrow M; Schlüter C; Galle J; Gerdes J
J Pathol; 1992 Dec; 168(4):357-63. PubMed ID: 1484317
[TBL] [Abstract][Full Text] [Related]
18. [Proliferative activity of stage I testicular neoplasms: evaluation by image analysis of immunoreactive MIB-1].
Martinazzi M; Zampieri A; Martinazzi S; Crivelli F; Mauri MF; Calandra C
Pathologica; 1998 Dec; 90(6):783-7. PubMed ID: 10220999
[TBL] [Abstract][Full Text] [Related]
19. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.
Moul JW; McCarthy WF; Fernandez EB; Sesterhenn IA
Cancer Res; 1994 Jan; 54(2):362-4. PubMed ID: 8275469
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in low-stage nonseminomatous testicular cancer.
Moul JW; Heidenreich A
Oncology (Williston Park); 1996 Sep; 10(9):1359-68, 1374; discussion 1377-8. PubMed ID: 8882926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
